Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan
Biogen and Eisai have jointly developed three experimental drugs for Alzheimer’s
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biogen
Glenmark Pharmaceuticals gets ANDA approval for multiple sclerosis drug
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (US FDA) for dimethyl…
Lupin gets US FDA approval for dimethyl fumarate delayed release capsules
According to IQVIA MAT June 2020 data, dimethyl fumarate delayed-release capsules had an annual sales of approximately USD 3788…
Mylan announces launch of generic version of Biogen’s Tecfidera
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS)
Biogen to study Spinraza in combination with $2-mn Novartis drug
The one-a-day oral drug is viewed as a potential a rival to Spinraza, which is administered every four months via spinal infusion
Biogen moves forward with potential Alzheimer’s drug, seeks US FDA’s approval
The drug, aducanumab, has had a tumultuous journey, with promising early data raising hopes and Biogen’s share price, only to be…
Healthcare industry reports 70 deals worth $3.2-bn in Jan ’20
The healthcare industry reported 98 VC deals worth $1.9-billion in January 2020, compared to the last 12-month average of 103…
Roche’s SMA drug trial win bolsters $2 billion sales prospects
US regulators are due to decide by May 24
Biogen to buy early-stage potential Alzheimer’s, Parkinson’s treatment from Pfizer
Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments
FDA approves Biogen and Alkermes’ multiple sclerosis drug
The approval is good news for Biogen as its top-selling drug Tecfidera, also a multiple sclerosis treatment, is facing patent…